|04/24/17||Fresenius Kabi to Acquire Akorn|
|- - - - -
Strategically complementary combination to enhance and diversify Fresenius Kabi’s business and portfolio
- - - - -
At $34.00 a share, transaction valued at approximately $4.3 billion, plus the assumption of debt
- - - - -
Transaction expected to close by early 2018LAKE ZURICH, Ill. and LAKE FOREST, Ill., April 24, 2017 – Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX), a U.S-based manufacturer and marketer of prescription and over-the-counter pharmaceutical... |
|04/07/17||Akorn Confirms Discussions with Fresenius Kabi|
|LAKE FOREST, Ill., April 07, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today confirmed that Akorn is currently in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA (FWB:FRE), concerning a potential acquisition of Akorn.
Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the Executive Board and Supervisory Board of Fresenius Management SE and t... |
|03/02/17||Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP|
|LAKE FOREST, Ill., March 02, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generics pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Ephedrine Sulfate Injection, USP 50 mg/mL in 1 mL single dose ampule. Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Akorn, I... |